Nervgen Pharma Corp NGEN

$5.97 +0.13 (2.23%)

Valuation

Market cap
—
Revenue TTM
$46,920,000
Net income TTM
$-38,100,000
PE ratio
—
Forward PE
0.00
Profit margin
-81.20%
Debt to equity
—

Trading

Volume
775,700
Avg volume
145,364
Day's range
$5.41 – $6.30
Shares out
—
Stochastic %K
80%
Beta
—
Analysts
Strong Buy
Price target
—

Price

Company profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300...

Show more

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
778 731 1711
Website
https://nervgen.com
Address
112-970 Burrard Street, Unit 1290, Vancouver, Canada

Latest news

Stocktwits

OldManLogan Oct 3, 10:21 PM
$NGEN It's interesting, I had the same thought about why they seem to have shied away from being explicit on which indications to pursue next... I.e they may be in some longterm discussions whereby they don't want to disclose that just now... though they wanted the message to be clear that they could jump into a late stage trial in any of those indications thanks to our existing phase 1 trial in healthy patients.
0 replies
Westjtter Oct 3, 3:19 PM
$NGEN So based on my previous post, the company is only looking for a very modest benefit to patients, for the trial to be a huge success! Based on this, the chances of a complete failure in the Restore trial is very low(but not zero). Of course if there were some miraculous results in this trial..... it would be difficult to put a value on the company. Again, I believe they will succeed and the risk is certainly worth the reward for me......I believe the share price will start to reflect this in the coming months! And if there are some huge wins(positive results) here in the trial participants....how do you keep that quiet? Could be an interesting year!
0 replies
Westjtter Oct 3, 3:10 PM
$NGEN So I would think that enrollment would be fairly rapid as they dropped the MEP requirement(measurement to assess respiratory muscle strength--highest possible pressure a patient can exert). Does this mean the results could be tempered somewhat or more dilutive than the ph 1/2 trial?? While a salient point, I would have to believe that the company would have considered this before dropping the requirement and so should not be an issue. Also the primary goal or efficacy measurement determinant is hand function, durability, gait and patient perceived benefit(seems a very modest bar to achieve). Based on results from the ph 1/2 trial and the patient testimonials, the Restore trial has a very high probability of success!
0 replies
libertyjc Oct 3, 2:16 PM
$NGEN apparently Jerry Silver tried to publish a paper on the successful effects of NVG 291 in the animal model for Alzheimers the results were so astoundingly positive - they were deemed unbelievable/uncredible and the paper was never published
3 replies
Floridaorange Oct 3, 1:46 PM
$NGEN Just my notes…
1 replies
TheSchrodingerCat Oct 2, 11:16 PM
$NGEN excellent overview by the moderator of biopub. WE DIDN'T get a clear picture of 1. Where Nervgen is heading in regards to new applications. 2. When and how much information they will share regarding the study as it is ongoing. and 3. Will the information even be shared by Neevgen or will they rely on third party actors such as Reddit to relay the information. I believe what Biopub has to say as they have their ear to the ground with the company.
2 replies
Tarquinjones Oct 2, 10:40 PM
$NGEN https://open.spotify.com/track/3dXUhi35uNdJ1eYewv1XBK?si=TPv0sIQkQ5qx2hkyfx_Akw&utm_source=copy-link
1 replies
libertyjc Oct 2, 8:20 PM
$NGEN fun fact…and data that hasn’t been focused on - but chronic SCI patients generally lose their sense of smell - in phase 2 data…most all treated with NVG-291 had substantial improves in smell
3 replies